This pattern gives a first target to return to level A at about 8.10-8.20 and a second target to return to level C at around 8.50.
Anticipated Catalysts for remaining 2022:
NA/US Licensing Vyleesi
ROW Licensing Vyleesi
PL3994 PH2 Heart Failure Data
Diabetic Nephropathy PH 2 Initiate Study
Something should also happen with the preferred shares at the end...
I just created this chart to better understand how PTN moved on the big spike recently. Seems like it didn't take much, just a Yahoo article after the positive dry eye news and then a few YouTube videos.
Here are the links to the article and videos:
12/22/2020 Michael Marcus -...
Let's see if volume confirms this breakout. A lot going on with this company right now. I believe with the Key Opinion Leader webinar tomorrow they are trying to increase institutional buying and possibly analyst coverage. Volatility with the stock over the past 5 years has allowed quite a bit of opportunity to repeatedly buy below .60 and sell above 1.20.
Although my target based on fundamentals is much higher for PTN. This harmonic pattern gives a .72 target.
Link below to my other PTN idea with fundamental outlooks on how we look moving forward.
Palatin Technologies is a little known pharmaceutical company that specializes in the development of peptide drugs.
Palatin Technologies (PTN) is severely undervalued with a Market Cap of about $180 Million as of 3/17/21.
Palatin has $72.2 Million in cash on hand as of 12/31/2020, and no debt.*
Palatin owns and recently began marketing FDA Approved Vyleesi, a drug...
